Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250017/S002

GORE VIABAHN FORTEGRA Venous Stent

W. L. Gore & Associates, Inc. · Decision date Mar 6, 2026

FDA DECISIONP250017/S002

What did the FDA decide?

FDA records P250017/S002 as a supplement to PMA P250017, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 6, 2026.

FDA approval order statement

changes to the delivery system tip bonding process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Mar 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P250017/S002
Regulatory pathway
PMA supplement
Product code
QTL
Decision code
OK30
Decision date
Mar 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, vena cava.

Product code
QTL
FDA device class
3

For the original device and its historical approval scope, see PMA P250017. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250017 · Original PMA

    GORE VIABAHN FORTEGRA Venous Stent

  2. P250017/S002 received

    Application receipt date recorded by FDA.

  3. P250017/S002 · FDA decision

    30-Day Notice

  4. P250017/S001 · Related supplement

    GORE VIABAHN FORTEGRA Venous Stent

  5. P250017/S003 · Related supplement

    GORE VIABAHN FORTEGRA Venous Stent

Timeline entries are records held by MedtechLedger for P250017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250017

Product / regulatory recordCompanyPathwayDecision dateSource
W. L. Gore & Associates, Inc.PMA approvalDec 19, 2025FDA
W. L. Gore & Associates, Inc.PMA supplementApr 7, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementApr 30, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1505 N Fourth St., Flagstaff, AZ, 86004

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records